Sunday - July 20, 2025
FRANKLIN, Tenn. / Nov 21, 2023 / Business Wire / Community Health Systems, Inc. (NYSE:CYH) today announced that management will participate in the 2023 BofA Securities Leveraged Finance Conference to be held November 27 – 29, 2023.
The investor presentation will begin at 8:50 a.m. Eastern time, 7:50 a.m. Central time, on Tuesday, November 28, 2023, and will be available to investors via a live audio webcast. A link to the broadcast can be found at the investor relations section of the Company’s website, www.chs.net, and a replay will be available using that same link.
About Community Health Systems, Inc.
Community Health Systems, Inc. is one of the nation’s largest healthcare companies. The Company's affiliates are leading providers of healthcare services, developing and operating healthcare delivery systems in 41 distinct markets across 15 states. CHS subsidiaries own or lease 74 affiliated hospitals with 12,000 beds and operate more than 1,000 sites of care, including physician practices, urgent care centers, freestanding emergency departments, occupational medicine clinics, imaging centers, cancer centers and ambulatory surgery centers. Shares in Community Health Systems, Inc. are traded on the New York Stock Exchange under the symbol “CYH.” The Company’s headquarters are located in Franklin, Tennessee, a suburb south of Nashville. More information about the Company can be found on its website at www.chs.net.
Last Trade: | US$3.59 |
Daily Change: | -0.05 -1.37 |
Daily Volume: | 1,611,106 |
Market Cap: | US$503.710M |
February 18, 2025 December 11, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load